Clinical trials: Nab-paclitaxel
Advanced Pancreatic Ductal Adenocarcinoma
KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.
This study is a multicenter, randomized, double-Blind Phase III Study to compare the clinical efficacy and safety of KN046 plus gemcitabine and nab-paclitaxel versus placebo plus gemcitabine and nab-paclitaxel in subjects with…
- Trial name
- NCT05149326
- Testing
- KN046
- Where
- 65 sites in China
- Volunteers
- 408 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Solid Tumor, Breast Cancer
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
The study consists of 2 parts. Part 1 is dose escalation and will first administer SY-5609 alone to participants with select advanced solid tumors and then in combination with fulvestrant to participants with HR positive…
- Conditions
- Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
- Trial name
- NCT04247126
- Testing
- SY-5609, Fulvestrant, Gemcitabine
- Where
- 16 sites in United States
- Volunteers
- 105 people
- Sponsor
- Syros Pharmaceuticals
Pancreatic Cancer, PDAC
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
- Conditions
- Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- RASolute 302 (NCT06625320)
- Testing
- RMC-6236, Gemcitabine, nab-paclitaxel
- Where
- 60 sites in United States, France and 5 more
- Volunteers
- 500 people
- Sponsor
- Revolution Medicines, Inc.
First-line Treatment of Metastatic Pancreatic Cancer
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
This study is a randomized, open-label, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of Irinotecan Hydrochloride Liposome Injection (II) combined with oxaliplatin and 5-FU/LV versus…
- Trial name
- NCT07238283
- Testing
- Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate, nab-paclitaxel; gemcitabine
- Where
- China
- Volunteers
- 662 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Neoplasms, Pancreatic Neoplasms
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small Cell Lung Cancer (NSCLC) and Metastatic Breast…
- Trial name
- NCT02309177
- Testing
- nab-Paclitaxel, Nivolumab, Gemcitabine
- Where
- 15 sites in United States
- Volunteers
- 114 people
- Sponsor
- Celgene
Solid Tumors
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the…
- Trial name
- NCT02762981
- Testing
- Relacorilant with nab-paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- Corcept Therapeutics
Solid Tumor
A Study of ASP3082 in Adults With Advanced Solid Tumors
This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors…
- Trial name
- NCT05382559
- Testing
- Setidegrasib, Cetuximab, Leucovorin
- Where
- 68 sites in United States, China and 5 more
- Volunteers
- 681 people
- Sponsor
- Astellas Pharma Inc
Pancreatic Neoplasms, Cholestasis
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
The purpose of this study is to determine the safety and pharmacokinetic profile of nab®-paclitaxel (ABI-007) plus gemcitabine in subjects with advanced pancreatic cancer who have cholestatic hyperbilirubinemia secondary to bile…
- Trial name
- NCT02267707
- Testing
- nab-paclitaxel, Gemcitabine
- Where
- 6 sites in United States, Germany
- Volunteers
- 1 people
- Sponsor
- Celgene
Pancreatic Cancer
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated…
- Trial name
- NCT02047500
- Testing
- TH-302, Nab-paclitaxel, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- ImmunoGenesis
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Non Small Cell Lung Cancer
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy…
- Trial name
- NCT03574649
- Testing
- Nab-paclitaxel, Cisplatin, 5Fluorouracil
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Advanced Pancreatic Cancer
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
Assessment of safety and tolerability of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in subjects with Advanced Pancreatic Carcinoma.
- Trial name
- NCT02101580
- Testing
- ADI-PEG 20
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Polaris Group
Triple-negative Breast Cancer
A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer
This is an open-label, phase Ib/II, multi-center study to evaluate efficacy and safety of KN046 alone or in combination with nab-paclitaxel in subjects with locally advanced unresectable or metastatic triple negative breast…
- Trial name
- NCT03872791
- Testing
- KN046, Nab-paclitaxel
- Where
- 12 sites in China
- Volunteers
- 52 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Solid Tumor
IN10018 Combination Therapy in Previously-treated Solid Tumors
This is a phase Ib/II, randomized, open-label, multicenter clinical trial to evaluate the antitumor activities, safety, tolerability and pharmacokinetics (PK) of IN10018 in combination with taxane and anti-PD-1/L1 monoclonal…
- Trial name
- NCT05982522
- Testing
- IN10018, Nab-paclitaxel, Tislelizumab
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Metastatic Breast Cancer
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab. The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients…
- Trial name
- NCT00394082
- Testing
- ABI-007, Bevacizumab
- Where
- 20 sites in United States
- Volunteers
- 50 people
- Sponsor
- Celgene
Advanced Solid Tumor, PIK3CA Mutation
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side…
- Conditions
- Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation
- Trial name
- NCT05300048
- Testing
- Serabelisib, Insulin Suppressing Diet, Nab paclitaxel
- Where
- 17 sites in United States
- Volunteers
- 34 people
- Sponsor
- Faeth Therapeutics
Metastatic Pancreatic Ductal Adenocarcinoma
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
The PANOVA-4 study is designed to evaluate the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with atezolizumab, gemcitabine and nab-paclitaxel, for the treatment of metastatic pancreatic cancer.
- Trial name
- NCT06390059
- Testing
- Tumor Treating Fields, Atezolizumab, Gemcitabine
- Where
- 15 sites in Czechia, Germany and 2 more
- Volunteers
- 84 people
- Sponsor
- NovoCure Ltd.
Locally Advanced Pancreatic Adenocarcinoma
Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Paclitaxel) in Adults With Locally Advanced Pancreatic Cancer (PANOVA-3CA)
The EF-54 program (PANOVA-3CA) is a continued access program for adults with locally advanced pancreatic cancer to access TTFields therapy in combination with gemcitabine and nab-paclitaxel.
- Trial name
- PANOVA-3CA (NCT07319910)
- Testing
- TTFields, Gemcitabine, Nab paclitaxel
- Sponsor
- NovoCure GmbH
Pancreatic Cancer, Pancreatic Cancer Metastatic
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- MAPKeeper 301 (NCT07562152)
- Testing
- Atebimetinib, GnP, mGnP
- Where
- 72 sites in United States, Australia and 7 more
- Volunteers
- 570 people
- Sponsor
- Immuneering Corporation
Malignant Neoplam, Advanced Solid Tumors
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
Researchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids.
- Trial name
- NCT07793942
- Testing
- MK-2010, Pembrolizumab, 5-Fluorouracil
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC